Evidence map›Paper›PMID 41999486›Full record

ArticleChild psychiatry and human development2026

Internal Validity of the French Version of the PARDI-AR-Q and Subtypes Analysis Among Children and Adolescents.

Bérengère Rubio, Natalie Rigal

Abstract read
PubMed Publisher
In one paragraph

Article in Child psychiatry and human development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bérengère RubioLaboratoire CLIPSYD (Clinique, Psychanalyse, Développement), Département de Psychologie, Université Paris Nanterre, UFR SPSE, 200 Avenue de La République, 92000, Nanterre Cedex, France. brubio@parisnanterre.fr.ORCID http://orcid.org/0000-0001-9714-6898
Natalie RigalLaboratoire CLIPSYD (Clinique, Psychanalyse, Développement), Département de Psychologie, Université Paris Nanterre, UFR SPSE, 200 Avenue de La République, 92000, Nanterre Cedex, France.ORCID http://orcid.org/0000-0002-5180-4346

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although avoidant/restrictive food intake disorder (ARFID) has been included in the Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 2013) as a distinct eating disorder category, research on ARFID remains scarce in France, primarily due to a lack of a French tool to assess its diagnosis. The objectives of this study were to provide a validated French-language assessment tool for ARFID and to examine the distribution of different ARFID subtypes (food avoidance based on sensory sensitivity, lack of interest in eating, fear of aversive consequences) in French children and adolescents, in the overall sample and by individuals' characteristics (i.e., age, gender). Using a translation and back-translation procedure, a French version of the PARDI-AR-Q was administered to 119 parents of children and adolescents with ARFID aged 2 to 16 years. Psychometric analyses supported the existence of the three subtypes with satisfactory internal consistency. Younger children had higher Sensory sensitivity and Lack of interest scores compared to older, while no sex differences were observed for the three subtypes. Hierarchical cluster analysis identified five ARFID profiles (two pure and three combined). These findings support the availability of a reliable French-language instrument for ARFID diagnosis and underscore the importance of recognizing mixed presentations to inform early detection and tailored clinical interventions.

Indexed as

AdolescentsARFIDAssessmentChildrenPARDI-AR-Q

Identifiers

PMID41999486

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.